Filing Flows › CG Oncology (CGON) › Q2 2026
CG Oncology (CGON) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
CG Oncology (CGON) reported revenue of $1.2M for the second quarter 2026 (Q2 2026) and +7% from the quarter before.
CG Oncology, Q2 2026: revenue $1.2M, net loss $79.1M, operating cash flow −$46.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | +7% | — |
| Operating profit | −$86.4M | — | — |
| Net earnings | −$79.1M | — | — |
| Operating cash flow | −$46.4M | — | — |
What changed
Revenue was $1.2M in Q2 2026, up 7% from the previous quarter. Commercial and Development Revenue was the largest line at 99% of revenue.
Operating costs exceeded revenue by $86.4M, an operating margin of -7467.7%. The quarter ended with a net loss of $79.1M, wider than the previous quarter's $60.2M loss.
Operating cash flow was −$46.4M. Non-cash charges added back $850K of depreciation and amortization and $14.3M of share-based compensation. Working capital and other items added $17.5M. Capital expenditures of $468K exceeded it, leaving free cash flow of −$46.9M.
Questions
What was CG Oncology's revenue in the second quarter 2026?
CG Oncology (CGON) reported revenue of $1.2M for the second quarter 2026 (Q2 2026) and +7% from the quarter before.
Source: CG Oncology 10-Q on SEC EDGAR.